New England Journal of Medicine publishes Diamyd Medical's antigen-based diabetes therapy study

“GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus”

An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England Journal of Medicine. The now published results were previously presented at the American Diabetes Association's 71st Scientific Sessions in San Diego, California, USA, on June 28, 2011.

The title of the published article is "GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus". The authors are J. Ludvigsson, D. Krisky, R. Casas, T. Battelino, L. Castaño, J. Greening, O. Kordonouri, T. Otonkoski, P. Pozzilli, J-J. Robert, H.J. Veeze and J. Palmer.

The article is available via the New England Journal of Medicine's website (www.nejm.org), and will also be published in the printed edition.

Results from Diamyd Medical's European Phase III study with Diamyd® were first reported in May 2011. The study did not meet the primary efficacy endpoint of preserving beta cell function, as measured by meal-stimulated C-peptide, although a small positive effect was seen. Safety data from the study showed that Diamyd® was well tolerated, as demonstrated by a similar number of adverse events reported in the groups treated with Diamyd® and in the placebo group.